Jesus F. San Miguel-Miguel

Pamplona, NC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 195 publications

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.

International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 22, 2026

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma.

Journal: Journal for immunotherapy of cancer

Published: February 25, 2026

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencing.

Journal: HemaSphere

Published: December 23, 2025

Study of post-translational modifications of p53 in multiple myeloma.

Study of post-translational modifications of p53 in multiple myeloma.

Journal: Blood cancer journal

Published: December 10, 2025

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry.

Journal: HemaSphere

Published: August 21, 2025

Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Erratum: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 25, 2025

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 09, 2025

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs.

Journal: Blood

Published: April 14, 2025

Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network.

Prevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network.

Journal: HemaSphere

Published: March 05, 2025

High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.

High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.

Journal: HemaSphere

Published: December 20, 2024

Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.

Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.

Journal: Clinical lymphoma, myeloma & leukemia

Published: October 22, 2024

Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.

Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.

Journal: American journal of hematology

Published: July 01, 2024

Showing 1-12 of 195

Last Updated: 09/26/2026